Articles tagged with Pharmacology
The health tech industry is evolving with AI-powered wearables that enable real-time data interpretation, reducing centralized infrastructure demands. Pharmaceutical AI tools like NoHarm automate reviews, freeing up resources for medication errors. These innovations transform healthcare, improving care and patient outcomes.
Vitiligo is an autoimmune disease where immune system attacks melanocytes, leading to skin patches. Researchers discovered dormant pigment cells that could be reactivated using pharmacological inhibitors. This finding suggests a new approach for treating vitiligo by restoring melanocyte function and pigmentation.
Researchers developed a framework to integrate AI into hospitals, emphasizing patient care, staff experience, and economic sustainability. The Total Mission Value framework aims to ensure high-quality patient care remains the top priority amidst AI's transformative potential.
A novel biological pathway has been uncovered that can lead to seizures when disrupted, providing a new approach for improved diagnosis. The study identifies an association between defective genes and increased glutamatergic transmission, which can increase the risk of seizures.
A systematic review and meta-analysis found that weight loss drugs can reduce key symptoms of binge eating disorder, including binge eating episodes, loss-of-control eating, and emotional eating. The study suggests that these medications could be an important part of treatment plans for people with binge eating disorder.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Researchers suggest separate weight-driven tables for different types of defendants, eliminating disparities in crack and methamphetamine sentences. The study proposes alternative approaches to define relative sentences for psychostimulants and opioids based on harms associated with each type of drug.
The study creates a radiohybrid approach that labels a single molecule with two different diagnostic radionuclides, enabling long-term visualization of therapeutic agent distribution. This allows for personalized cancer medicine by calculating optimal radiation doses for individual patients.
Researchers identify a promising new strategy to overcome drug resistance in deadly brain cancer by blocking nitrosative stress. Combining BA-101 with temozolomide slows tumor growth, reduces cancer's ability to spread, and increases cancer cell death.
Glial cells play critical roles in determining brain recovery after TBI, and researchers have identified ways to selectively modulate their functions. The study highlights the importance of coordinated cellular behavior and suggests that targeting glial responses could lead to effective therapies.
Researchers developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. The approach targets multiple disease-relevant cellular pathways, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
A new aptamer selection strategy termed extracellular vesicle (EV)-SELEX has been developed to rapidly identify highly specific DNA aptamers targeting G protein-coupled receptors. The EV-SELEX platform exploits a natural cellular process to minimize interference and efficiently select biologically relevant receptor conformations.
A new study links tire pollution to Alzheimer's disease through the exposure to 6PPD-quinone, a chemical formed from shaved-off tire particles. The researchers used computational methods to identify key genes that predict Alzheimer's disease and found strong binding of 6PPD-quinone to these genes.
A new review reveals autophagy's complex role in neuropathic pain, with moderate protection in neurons and pro-inflammatory effects in astrocytes and microglia. Targeting autophagy may address both pain and its emotional comorbidities like anxiety and depression.
A patient-derived KDF1 mutation impairs enamel-forming cells by disrupting cell adhesion and Hippo-YAP signaling. Mutant mice exhibit thinner enamel, reduced mineral density, and delayed tooth eruption.
A CU Anschutz study reveals reduced mitochondrial efficiency in healthy yet sedentary individuals, which may precede the development of major diseases like cancer, diabetes, and Alzheimer's. Regular exercise acts as a literal shield for cellular health, helping mitochondria seamlessly switch between burning fat and carbohydrates.
Researchers propose protein coronas as a dynamic navigation interface to shape how nanomedicines are recognized and delivered across the blood-brain barrier. The corona can be manipulated to bias circulation, targeting ligands, and intracellular trafficking for improved brain delivery.
Researchers present a roadmap for developing Tregs as adaptable therapies to restore immune balance and support tissue repair. This approach holds promise for treating conditions such as metabolic and cardiovascular disease, as well as neurodegeneration.
Gramine, a natural indole alkaloid, exerts potent anti-tumor effects against triple-negative breast cancer (TNBC) by inducing ferroptosis. The compound selectively targets TNBC cells while sparing normal mammary epithelial cells.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
New therapies using regulatory T cells, known as Tregs, could target diseases with inflammation, such as cancer and autoimmune conditions. Early evaluations show good tolerance and safety profiles, but precision is key to tailoring treatments for specific patients.
Large language models can accurately identify reasons for medication discontinuation from doctors' electronic clinical notes, revealing that adverse reactions are a common cause. The study uses this approach to transform clinical free text into analyzable data, supporting evidence-based decision-making in health policy.
Scientists have identified a unique chimeric RNA called UBA1-CDK16 that plays important roles in women's blood cell development and disease severity. The findings suggest the chimeric RNA may serve as a natural brake to protect women from excessive autoimmune activity.
A large-scale Phase 3 trial of CRISPR therapy has shown an 87% reduction in attacks for patients with hereditary angioedema. The treatment also improved quality-of-life scores and reduced the need for on-demand medication, paving the way for future genetic therapies.
The Acceleration Consortium and Structural Genomics Consortium collaborate to develop new drugs using AI-driven lab capabilities. The partnership aims to speed up the discovery of bioactive molecules, advancing human health and disease understanding.
Researchers found that temperature and calcium levels inside cells can dramatically impact how drugs interact with their targets. This discovery could lead to smarter medicine design and more effective treatments.
Researchers propose reconsidering how histone deacetylase inhibitors work in cancer treatment, identifying genuine molecular targets as a key step to improve treatment. The study suggests that HDAC inhibitors may interfere with other proteins, suppressing cancer growth.
The new vaccine adjuvant induces a strong mucosal immune response in the GI tract, which is crucial for eradicating polio. The researchers achieved a 20-fold increase in antibodies needed for mucosal immunity compared to the existing injectable polio vaccine.
Researchers developed a new platform to visualize drug-tumor interactions, allowing them to measure drug delivery and signaling in human solid tumors. This approach revealed pronounced spatial heterogeneity in drug delivery and target engagement across different tumor types.
A major real-world study by University of California, Irvine researchers found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies. Researchers discovered that some ADCs were linked to substantial rates of severe neutropenia and related complications.
Researchers developed a miniaturized human intestine model to study EV-A71 infection, revealing the virus's ability to evade the immune system and persist for extended periods. The model showed long-term viral replication without triggering a strong immune response.
Scientists create a moiré metasurface to map right- and left-handed regions in materials, visualizing chirality as two-dimensional images. The new approach resolves chirality distributions with a resolution of approximately 100 μm.
Researchers are using 3D cardiac constructs to model cardiovascular diseases and test new drugs. These constructs can capture the complexity of human cardiac tissue, including its electrical activity, metabolism, and cellular communication. The field is advancing with biomaterials, AI-assisted screening, and improved standardization.
A study by EHU researchers found that exercising outdoors can help combat vitamin D deficiency and strengthen the immune system. The study suggests that taking vitamin D supplements has no direct effect on physical performance, contrary to popular belief.
Researchers developed a new eye drop treatment that significantly reduced dry eye disease characteristics, such as inflammation and loss of goblet cells. The treatment uses a rexinoid compound that boosts the protective role of resident macrophages, promoting debris-clearing and immune balance.
The new edition of the Wiley Registry of Mass Spectral Data 2026 expands compound coverage to over 915,500 reference spectra, strengthening a foundational layer of scientific data and research intelligence. This expansion enables researchers to identify unknown chemical compounds and materials faster with confidence.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
A major new study has found that severe asthma patients are often battling other health conditions, with nearly all suffering from at least one major issue. The study identified three distinct profiles linked to how well asthma is controlled and the treatments needed, offering potential breakthroughs for improving care.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
A new statistical approach used in Alzheimer's disease trials may exaggerate the link between amyloid reduction and cognitive benefits of new drugs. Researchers found that combining large groups of patients can hide variability and make it appear as if reducing amyloid is more predictive of cognitive benefit than it actually is.
Researchers at Mizzou's Molecular Imaging and Theranostics Center developed an automated approach to producing the prostate cancer treatment. The new method produces CTT1403 in just 38 minutes, compared to six hours with traditional methods, using a commercially available automated synthesis system.
Researchers developed a new scale to estimate the risk of using medicines while driving, combining factors such as adverse effects and dosage. The FMB scale offers greater resolution than existing systems like DRUID, allowing for more precise identification of medicines with similar profiles.
Recent advances in medications, devices, and care pathways are redefining heart failure (HF) treatment. Emerging therapies beyond traditional EF silos have demonstrated broad efficacy across LVEF categories.
Researchers at Leibniz Institute for Food Systems Biology found that bitter-tasting herbal extracts stimulate proton secretion in human gastric cells, with polyphenol-rich extracts showing the strongest effects. The study identified three human bitter taste receptor subtypes as key mediators of this response.
Researchers developed genESOM, a generative AI that can expand dataset volume and simulate larger animal numbers while maintaining reliability. This allows for 30-50% reduction in animal experiments without compromising results.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The article systematically summarizes forty years of discoveries in the TLR field, revealing multilayered regulatory mechanisms governing TLR signaling. Aberrant TLR signaling is closely linked to multiple human diseases, including infectious diseases, autoimmune conditions, and cancer.
A new study from the University of Virginia finds that next-generation GLP-1 drugs can alter brain circuits controlling motivation and reward. The research shows that these drugs not only suppress appetite but also influence how the brain values food, helping explain their effectiveness and side effects.
Researchers engineer bacterial vesicles into multifunctional tools that can kill pathogens, boost vaccines, and deliver targeted therapies. Engineered BEVs address key limitations of existing therapies, including improving vaccine responses and antibiotic delivery.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Two UVA scientists, Edward H. Egelman and James N. Galloway, were elected to the prestigious American Academy of Arts & Sciences for their outstanding contributions to biochemistry, environmental sciences, and research. The recognition acknowledges their collective breadth and depth of excellence in advancing public good.
Researchers aim to develop novel quantum algorithms for molecular simulation, targeting computational bottlenecks in drug discovery. The collaboration combines expertise in quantum chemistry and sampling techniques with quantum computing capabilities.
A research consortium has developed mini-antibodies that can reactivate mutated p53, a key tumor suppressor protein. These DARPins bind selectively to p53 mutants, restoring stability and functionality, making them potentially useful against various types of tumors.
A $456,000 grant from Critical Path Institute will support the development of a brain-penetrant therapy for glycosphingolipid storage disorders. The therapy aims to address neurological symptoms in patients with current limited treatment options.
Researchers at the University of East Anglia have discovered that light can be programmed using its natural geometry, allowing for the creation of structured light with unique properties. This breakthrough has far-reaching implications for fields such as medicine, data transmission, and quantum technologies.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.